КЛОЙД Джеймс (US),БЕРНБОМ Анджела (US),ЛЕППИК Ило (US),КОЛЛИНЗ Стефен (US)
申请号：
RU2012112839/15
公开号：
RU2012112839A
申请日:
2012.04.02
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. The inclusion complex of carbamazepine-cyclodextrin, which can be used for parenteral administration of carbamazepine, including carbamazepine, bound in a complex with a modified cyclodextrin. 2. The complex of claim 1, wherein said modified cyclodextrin is sulfoalkyl-cyclodextrin. The complex according to claim 1 or 2, wherein said modified cyclodextrin is sulfobutyl ether-7-beta-cyclodextrin. The complex according to claim 1, having a concentration of from about 5 to about 50 mg / ml carbamazepine. The complex according to claim 1, having a concentration of approximately 10 mg / ml carbamazepine. A carbamazepine-cyclodextrin inclusion complex that can be used for parenteral administration of carbamazepine, in which the dosage is from about 30% to about 100% of the oral maintenance doses. The complex according to claim 6, wherein said dosage is from about 65% to 75% of oral maintenance doses. A carbamazepine-cyclodextrin inclusion complex that can be used for parenteral administration of carbamazepine having a half-life of from about 8 to about 65 hours. 9. The complex of claim 8, having a half-life of approximately 24 hours 10. A carbamazepine-cyclodextrin inclusion complex, which can be used for parenteral administration of carbamazepine, having an area under the plasma concentration curve (AUC) of about 70% to about 130% AUC for the oral dosage form of carbamazepine. 11. The complex of claim 10, having an AUC from about 80% to about 125% AUC for the oral dosage form of carb1. Комплекс включения карбамазепина-циклодекстрина, который можно применять для парентерального введения карбамазепина, включающий карбамазепин, связанный в комплекс с модифицированным циклодекстрином.2. Комплекс по п.1, где указанный модифицированный циклодекстрин представляет собой сульфоалкил-циклодекстрин.3. Комплекс по п.1 или 2, где указанный модифицированный циклодекстрин представляет собой сульфобутилэфир-7-бета-циклодекстрин.4. Комплекс по п.1, имеющий концентрацию от приблизительн
